.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Cantor Fitzgerald
McKinsey
Deloitte
Fish and Richardson
Dow
US Army
Chinese Patent Office
Colorcon

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,362,085

« Back to Dashboard

Which drugs does patent 8,362,085 protect, and when does it expire?


Patent 8,362,085 protects NAMENDA XR and NAMZARIC and is included in two NDAs. There have been zero Paragraph IV challenges on Namzaric and

Protection for NAMENDA XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 8,362,085

Title:Method for administering an NMDA receptor antagonist to a subject
Abstract: The invention provides methods for administering memantine to a subject. Memantine in an extended release form containing 22.5 to 30 mg memantine or a pharmaceutically acceptable salt is administered to a patient suffering from a neurological condition, such as Alzheimer's disease, Parkinson's disease or dementia. The extended release form achieves particular pharmacokinetic criteria such as change in plasma concentration of memantine over time and ratio of maximum memantine plasma concentration to mean memantine plasma concentration.
Inventor(s): Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Pleasant Hill, CA), Meyerson; Laurence R. (Las Vegas, NV)
Assignee: Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:13/536,525
Patent Claim Types:
see list of patent claims
Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-001Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-002Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-003Jun 21, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMENDA XRmemantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL022525-004Jun 21, 2010ABRXYesYes► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-003Jul 18, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-001Dec 23, 2014ABRXYesNo► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-004Jul 18, 2016RXYesNo► Subscribe► Subscribe► SubscribeY
Forest Labs LlcNAMZARICdonepezil hydrochloride; memantine hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL206439-002Dec 23, 2014ABRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Queensland Health
Novartis
Accenture
Chinese Patent Office
McKesson
Healthtrust
AstraZeneca
Citi
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot